Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
August 31, 2017 4:01 PM EDTATLANTA, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ: AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017.
We have made great strides, working with our Board and financial advisors, in honing in on a select number of strategic alternatives, commented Joseph M. Patti, PhD, President and Chief Executive Officer of Aviragen Therapeutics. Importantly, we have also taken actions to minimize cash spending in order to maintain the Companys solid financial position as evidenced by our reported cash position of $38.6 million.
... More